Stockscreener 앱 받기
6.41
0.63%
0.04
시간 외 거래:
6.30
-0.11
-1.72%
전일 마감가:
$6.37
열려 있는:
$6.21
하루 거래량:
20,232
Relative Volume:
0.21
시가총액:
$103.19M
수익:
-
순이익/손실:
$-14.88M
주가수익비율:
-6.5408
EPS:
-0.98
순현금흐름:
$-10.29M
1주 성능:
+3.89%
1개월 성능:
+17.61%
6개월 성능:
-4.90%
1년 성능:
-26.15%
1일 변동 폭
$6.126
$6.5306
1주일 범위
$5.86
$6.64
52주 변동 폭
$4.65
$10.24
Coya Therapeutics Inc Stock (COYA) Company Profile
명칭
Coya Therapeutics Inc
전화
650.739.3939
주소
12645 MEMORIAL DR., SUITE F1 #305, HOUSTON
COYA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
COYA
Coya Therapeutics Inc
|
6.41 | 103.19M | 0 | -14.88M | -10.29M | -0.98 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.92B | 3.81B | -644.79M | -669.77M | -6.24 |
Coya Therapeutics Inc Stock (COYA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-04 | 개시 | D. Boral Capital | Buy |
Coya Therapeutics Inc 주식(COYA)의 최신 뉴스
How To Trade (COYA) - news.stocktradersdaily.com
Coya Therapeutics, Inc. (NASDAQ:COYA) Shares Acquired by Geode Capital Management LLC - Defense World
Coya Therapeutics advances COYA 303 for inflammatory diseases - MSN
Is Coya Therapeutics, Inc. (COYA) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Coya Therapeutics’ (COYA) “Buy” Rating Reaffirmed at Chardan Capital - Defense World
Biotech Company Reports Promising Neurological Treatment in Clinical Study - streetwisereports.com
Coya Therapeutics: Treg Proof-Of-Concept Continues With Interim FTD Data Release - Seeking Alpha
Coya Therapeutics Announce Positive Interim Result from - openPR.com
Coya Therapeutics Announces Positive Interim Results of an Investigator-Initiated Open Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Five Patients with Mild to Moderate Frontotemporal Dementia – EventsNewsAsia.com - eventsnewsasia.com
Biotech Discovers Revolutionary Immunotherapy in Houston - streetwisereports.com
Coya stock in focus after interim results for dementia drug - Seeking Alpha
Coya Reports Positive Data From Proof Of Concept Open-label Study Of IL-2 And CTLA4-Ig Combo In FTD - Nasdaq
Coya Therapeutics Announces Positive Interim Results of an Investigator-Initiated Open Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Five Patients with Mild to Moderate Frontotemporal Dementia - businessnews.ph
Coya Therapeutics Announces Positive Interim Results Of An Investigator-Initiated Open Label Study With Low-Dose IL-2 And CTLA4-Ig Combination Treatment In Five Patients With Mild To Moderate Frontotemporal Dementia - marketscreener.com
Revolutionary Frontotemporal Dementia Treatment Prevents Cognitive Decline in All Trial Patients - Stock Titan
Coya Therapeutics (NASDAQ:COYA) Earns Buy Rating from D. Boral Capital - Defense World
Wall Street Analysts See a 144.73% Upside in Coya Therapeutics, Inc. (COYA): Can the Stock Really Move This High? - Yahoo Finance
AI in Clinical Trials Market Growth 2025: Trends, Consumer - openPR.com
Coya Therapeutics (NASDAQ:COYA) Trading 8.6% Higher – What’s Next? - Defense World
Coya Therapeutics, Inc. Announces Publication of GLP-1/LD IL-2 Combination Biologic (COYA 303) Demonstrating Synergistic Enhancement of Regulatory T Cell Function and Protection Against Treg Apoptosis (Cell Death) - marketscreener.com
Coya Therapeutics (COYA) Reports Promising Study Results for COY - GuruFocus
(COYA) Long Term Investment Analysis - news.stocktradersdaily.com
Is Coya Therapeutics (COYA) the Top Healthcare Stock to Buy According to Billionaire David Einhorn? - Yahoo
Coya Therapeutics stock hits 52-week low at $4.72 - Investing.com Australia
Coya Therapeutics stock hits 52-week low at $4.72 By Investing.com - Investing.com Canada
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Exosomes Pipeline 2025: MOA and ROA Insights, Clinical Trials - openPR.com
Coya Therapeutics Selected for Platform Presentation at the ADPD 2025 Conference in Vienna on April 5, 2025 - The Joplin Globe
GMP Production of Exosomes Slated for Later This Year - streetwisereports.com
D. Boral Capital Reiterates Buy Rating for Coya Therapeutics (NASDAQ:COYA) - Defense World
Biotech Advances Revolutionary Treatment for Neurodegenerative Diseases - Streetwise Reports
What is Chardan Capital’s Forecast for COYA FY2025 Earnings? - Defense World
What Makes Coya Therapeutics, Inc. (COYA) a New Buy Stock - Yahoo Finance
Wall Street Analysts Think Coya Therapeutics, Inc. (COYA) Could Surge 149.62%: Read This Before Placing a Bet - Yahoo Finance
Are Medical Stocks Lagging Auna S.A. (AUNA) This Year? - Yahoo Home
Coya Therapeutics advances Treg exosome production By Investing.com - Investing.com South Africa
Coya Therapeutics advances Treg exosome production - Investing.com India
Coya Therapeutics Reports Progress from an Academic Supported First-in-Class Treg-derived Exosome Program - Joplin Globe
Revolutionary Treg Exosome Treatment Could Transform Neurodegenerative Disease Therapy - Stock Titan
Agitation in Alzheimer's Disease Market: Analysis - openPR.com
(COYA) Trading Report - news.stocktradersdaily.com
Coya Therapeutics (NASDAQ:COYA) Earns Buy Rating from Chardan Capital - Defense World
Coya Therapeutics Reports 2024 Financial Results and Progress - TipRanks
Coya Therapeutics to Present ALS Clinical Study Data for its Investigational Biologic Combination at the 2023 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference. - Business Wire
Coya Therapeutics (NASDAQ:COYA) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance
BTIG maintains Buy on Coya Therapeutics, target at $15 By Investing.com - Investing.com Canada
Coya Therapeutics’ (COYA) Buy Rating Reaffirmed at D. Boral Capital - Defense World
Coya Therapeutics Reports 2024 Financial Results and Updates - TipRanks
Coya Therapeutics Inc (COYA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.39%
3.66%
자본화:
|
볼륨(24시간):